Public Employees Retirement Association of Colorado Cuts Position in Catalent, Inc. (NYSE:CTLT)

Public Employees Retirement Association of Colorado trimmed its position in shares of Catalent, Inc. (NYSE:CTLT) by 4.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,679 shares of the company’s stock after selling 793 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Catalent were worth $1,050,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lindbrook Capital LLC raised its stake in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent during the 2nd quarter valued at about $42,000. Mather Group LLC. bought a new position in shares of Catalent in the 1st quarter valued at about $52,000. Longfellow Investment Management Co. LLC grew its position in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CTLT shares. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Barclays boosted their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Robert W. Baird restated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Finally, StockNews.com initiated coverage on shares of Catalent in a research report on Wednesday, September 18th. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $59.83.

Catalent Price Performance

Catalent stock opened at $60.14 on Wednesday. The stock has a market cap of $10.88 billion, a price-to-earnings ratio of -9.86, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. The firm has a 50-day moving average of $59.56 and a two-hundred day moving average of $57.27. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. On average, research analysts forecast that Catalent, Inc. will post 1.06 earnings per share for the current year.

Insider Transactions at Catalent

In related news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Catalent news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares in the company, valued at $2,360,264.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the transaction, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,409 shares of company stock valued at $782,923. 0.31% of the stock is currently owned by corporate insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.